Henry Schein to Webcast Fourth Quarter and Full-Year 2023 Conference Call and Introduce Its Full-Year 2024 Guidance on Tuesday, February 27, 2024 at 10:00 A.M. ET
2024年1月23日 - 8:30PM
ビジネスワイヤ(英語)
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider
of health care solutions to office-based dental and medical
practitioners, announced today that it will release its fourth
quarter and full-year 2023 financial results before the stock
market opens on Tuesday, February 27, 2024, and will provide a live
webcast of its earnings conference call on the same day beginning
at 10:00 a.m. Eastern time. The Company will also introduce its
earnings expectations for the full-year 2024.
Speakers on the call will include Stanley M. Bergman, Chairman
of the Board and Chief Executive Officer of Henry Schein, and
Ronald N. South, Senior Vice President and Chief Financial
Officer.
Investors can access the call by visiting
https://investor.henryschein.com/webcasts. A replay will be
available on the Henry Schein website following the
presentation.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private
Securities Litigation Reform Act of 1995, we provide the following
cautionary remarks regarding important factors that, among others,
could cause future results to differ materially from the
forward-looking statements, expectations and assumptions expressed
or implied herein. All forward-looking statements made by us are
subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance and achievements or industry results to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. These statements are generally identified by the use of
such terms as “may,” “could,” “expect,” “intend,” “believe,”
“plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,”
“to make” or other comparable terms. Factors that could cause or
contribute to such differences include, but are not limited to,
those discussed in the documents we file with the Securities and
Exchange Commission (SEC), including our Annual Report on Form
10-K. Forward looking statements include the overall impact of the
Coronavirus Disease 2019 (COVID-19) on us, our results of
operations, liquidity and financial condition (including any
estimates of the impact on these items), the rate and consistency
with which dental and other practices resume or maintain normal
operations in the United States and internationally, expectations
regarding PPE products and COVID-19 related product sales and
inventory levels, whether additional resurgences or variants of the
virus will adversely impact the resumption of normal operations,
whether supply chain disruptions will adversely impact our
business, the impact of integration and restructuring programs as
well as of any future acquisitions, general economic conditions
including exchange rates, inflation and recession, and more
generally current expectations regarding performance in current and
future periods. Forward looking statements also include (i) our
ability to have continued access to a variety of COVID-19 test
types, and COVID-19 vaccines and ancillary supplies, and (ii)
expectations regarding COVID-19 test sales, demand and inventory
levels.
Risk factors and uncertainties that could cause actual results
to differ materially from current and historical results include,
but are not limited to: risks associated with COVID-19 and any
variants thereof, as well as other disease outbreaks, epidemics,
pandemics, or similar wide-spread public health concerns and other
natural disasters; our dependence on third parties for the
manufacture and supply of our products; our ability to develop or
acquire and maintain and protect new products (particularly
technology products) and technologies that achieve market
acceptance with acceptable margins; transitional challenges
associated with acquisitions, dispositions and joint ventures,
including the failure to achieve anticipated synergies/benefits;
legal, regulatory, compliance, cybersecurity, financial and tax
risks associated with acquisitions, dispositions and joint
ventures; certain provisions in our governing documents that may
discourage third-party acquisitions of us; adverse changes in
supplier rebates or other purchasing incentives; risks related to
the sale of corporate brand products; effects of a highly
competitive (including, without limitation, competition from
third-party online commerce sites) and consolidating market; the
repeal or judicial prohibition on implementation of the Affordable
Care Act; changes in the health care industry; risks from expansion
of customer purchasing power and multi-tiered costing structures;
increases in shipping costs for our products or other service
issues with our third-party shippers; general global and domestic
macro-economic and political conditions, including inflation,
deflation, recession, fluctuations in energy pricing and the value
of the U.S. dollar as compared to foreign currencies, and changes
to other economic indicators, international trade agreements,
potential trade barriers and terrorism; failure to comply with
existing and future regulatory requirements; risks associated with
the EU Medical Device Regulation; failure to comply with laws and
regulations relating to health care fraud or other laws and
regulations; failure to comply with laws and regulations relating
to the collection, storage and processing of sensitive personal
information or standards in electronic health records or
transmissions; changes in tax legislation; risks related to product
liability, intellectual property and other claims; litigation
risks; new or unanticipated litigation developments and the status
of litigation matters; risks associated with customs policies or
legislative import restrictions; cyberattacks or other privacy or
data security breaches; risks associated with our global
operations; our dependence on our senior management, employee
hiring and retention, and our relationships with customers,
suppliers and manufacturers; and disruptions in financial markets.
The order in which these factors appear should not be construed to
indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that
many of these factors are beyond our ability to control or predict.
Accordingly, any forward-looking statements contained herein should
not be relied upon as a prediction of actual results. We undertake
no duty and have no obligation to update forward-looking statements
except as required by law.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for
health care professionals powered by a network of people and
technology. With more than 23,000 Team Schein Members worldwide,
the Company's network of trusted advisors provides more than 1
million customers globally with more than 300 valued solutions that
help improve operational success and clinical outcomes. Our
Business, Clinical, Technology, and Supply Chain solutions help
office-based dental and medical practitioners work more efficiently
so they can provide quality care more effectively. These solutions
also support dental laboratories, government and institutional
health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 300,000 branded
products and Henry Schein corporate brand products in our main
distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index,
Henry Schein is headquartered in Melville, N.Y., and has operations
or affiliates in 33 countries and territories. The Company's sales
reached $12.6 billion in 2022, and have grown at a compound annual
rate of approximately 12.1 percent since Henry Schein became a
public company in 1995.
For more information, visit Henry Schein at www.henryschein.com,
Facebook.com/HenrySchein, and @HenrySchein on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240122164576/en/
Investors Ronald N. South Senior
Vice President and Chief Financial Officer
ronald.south@henryschein.com (631) 843-5500
Graham Stanley Vice President, Investor Relations and Strategic
Finance Project Officer graham.stanley@henryschein.com (631)
843-5500
Media Ann Marie Gothard Vice
President, Global Corporate Media Relations
annmarie.gothard@henryschein.com (631) 390-8169
Henry Schein (NASDAQ:HSIC)
過去 株価チャート
から 4 2024 まで 5 2024
Henry Schein (NASDAQ:HSIC)
過去 株価チャート
から 5 2023 まで 5 2024